Jungraithmayr Wolfgang
Department of Thoracic Surgery, University Hospital Freiburg, Freiburg, Germany.
Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
Front Physiol. 2020 Dec 18;11:581420. doi: 10.3389/fphys.2020.581420. eCollection 2020.
Lung ischemia reperfusion (IR) injury inevitably occurs during lung transplantation. The pulmonary endothelium is the primary target of IR injury that potentially results in severe pulmonary dysfunction. Over the last decades, various molecules, receptors, and signaling pathways were identified in order to develop treatment strategies for the preservation of the pulmonary endothelium against IR injury. We here review the latest and most promising therapeutic strategies for the protection of the endothelium against IR injury. These include the stabilization of the endothelial glycocalyx, inhibition of endothelial autophagy, inhibition of adhesion molecules, targeting of angiotensin-converting enzyme, and traditional viral and novel non-viral gene transfer approaches. Though some of these strategies proved to be promising in experimental studies, very few of these treatment concepts made the transfer into clinical application. This dilemma underscores the need for more experimental evidence for the translation into clinical studies to invent therapeutic concepts against IR injury-mediated endothelial damage.
肺移植过程中不可避免地会发生肺缺血再灌注(IR)损伤。肺内皮是IR损伤的主要靶点,这可能导致严重的肺功能障碍。在过去几十年中,人们确定了各种分子、受体和信号通路,以制定保护肺内皮免受IR损伤的治疗策略。我们在此综述保护内皮免受IR损伤的最新且最具前景的治疗策略。这些策略包括稳定内皮糖萼、抑制内皮自噬、抑制黏附分子、靶向血管紧张素转换酶,以及传统的病毒和新型非病毒基因转移方法。尽管其中一些策略在实验研究中被证明很有前景,但这些治疗概念中很少能转化为临床应用。这种困境凸显了需要更多实验证据来转化为临床研究,以发明针对IR损伤介导的内皮损伤的治疗概念。